Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery - RCT

NCT ID: NCT02745288

Last Updated: 2016-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mandibular resection which is an important component of maxillofacial cancer surgery is an extremely painful procedure associated with severe sympathetic response needing high doses of opioids. Inferior alveolar nerve block is a common nerve block used by dentists for mandibular dental extractions. The aim of this trial is to study the effect of this block for intraoperative analgesia in maxillofacial cancer surgeries requiring unilateral mandibular resection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All adult patients below 75yrs of age scheduled for maxillofacial surgery will be screened for inclusion and exclusion criteria.

Written informed consent will be taken one day prior to surgery. Consenting subjects will be randomized after induction of anaesthesia to study or control arm.

The duration of the study is from induction of anaesthesia to the completion of primary tumour removal and neck dissection

Study procedure: Ipsilateral Inferior alveolar nerve block A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.

The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.

Control arm will not receive any intervention. The study investigator will give a mock injection for blinding of the attending anaesthetist

The study procedure will be done by the study investigators 10 -30 minutes prior to commencing surgery for primary tumour.

Account of procedure:

All patients will have standard conduct of anaesthesia except for the alveolar nerve injection in the study group.

All patients will have the minimum standard monitoring of pulse oximeter, electrocardiogram, capnography and non invasive blood pressure monitoring.

Blood pressure and heart rate will be recorded every 5 min interval from the beginning till completion of primary tumor excision and neck dissection

Induction of anaesthesia: IV fentanyl 2 mcg/kg, IV Propofol 2 -3 mg/kg. IV neuromuscular blocking agent used will be Inj vecuronium bromide in the dose of 0.1 mg /kg. All patients will have standard airway management at the discretion of the attending anaesthesiologist.

Intraoperative maintenance of anaesthesia will be as follows

1. Controlled ventilation with isoflurane in air / oxygen with minimal alveolar concentration of 0.8 -1.2
2. Intraoperative analgesic - IV fentanyl in boluses of 1 mcg/kg at the discretion of the anaesthetist based on the haemodynamic response till the completion of primary tumour removal and neck dissection. Thereafter, the choice of analgesic will be left to the anaesthetist
3. In case of uncontrolled sympathetic response (hypertension and/or tachycardia) to surgery not controlled by IV fentanyl (10 mcg/kg ), rescue intraoperative analgesic/ anaesthetic (e.g.IV morphine, IV diclofenac, IV dexmedetomide, IV propofol, increase in inhalational anaesthetic concentration, etc) or vasoactive agents (e.g.IV Esmolol, IV Nitroglycerin, etc) may be used. This will be noted in the Case record form.

Information will be collected as per Case Record form by the investigator. Any deviation from protocol will be recorded.

Sample size calculation Based on the average fentanyl requirement 340mcg found in pilot data, to detect 25% reduction in fentanyl requirement in the study group compared to control group, with 80% power and level of significance of 5% ,the sample size calculated was 22 in each group.

Statistical Analysis The fentanyl requirement in the two groups, maximum heart rate and maximum blood pressure will be will be compared using students t test Other variables will be described as numbers and percentage

Demographic ,clinical and disease relate variable will be present as frequency (percentage) and mean (S.D.) or median as appropriate.

Two group comparisons will be made using independent t-test or Man Whitney U test as per distribution of the data.

P-value\< 0.05 will be considered statistical significant. Repeated measures ANOVA will be used to compare change of blood pressure and heart rate from baseline at various time points.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mandibular Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nerve block

This arm will receive inferior alveolar nerve block

Group Type EXPERIMENTAL

inferior alveolar nerve block

Intervention Type PROCEDURE

A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.

The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.

control

Control arm will not receive inferior alveolar block

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

inferior alveolar nerve block

A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.

The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients between the age of 18 and 75 yrs classified as ASA I and II physical status requiring maxillofacial cancer surgery requiring unilateral mandibular resection and unilateral neck dissection

Exclusion Criteria

* \- surgery involving upper alveolar / maxillary resection
* patients with BMI below 18kg/m2 and above 30kg/m2
* allergy to local anaesthetic agent
* Inability to give inferior alveolar nerve block due to any cause e.g. restricted mouth opening, obscured landmark or infection at site
* pregnant women
* patients unable to give valid consent e.g. patients with learning difficulties
* patients on medications for hypertension
* patients with preoperative pain requiring regular pain medications
* uncontrolled haemodynamic status e.g. baseline arterial blood pressure above 160 /90 and baseline HR above 100 /min
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tata Memorial Centre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Madhavi Shetmahajan

Associate professor, dept of anaethesia

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Madhavi Shetmahajan, MD

Role: PRINCIPAL_INVESTIGATOR

Tata Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tata Memorial Hospital

Mumbai, India, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1648

Identifier Type: -

Identifier Source: org_study_id